Amberstone Biosciences snags $12m Series A
Amberstone Biosciences, an emerging biotherapeutics company, has closed $12 million in Series A financing.
Amberstone Biosciences, an emerging biotherapeutics company, has closed $12 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination